Comparative Pharmacology
Head-to-head clinical analysis: MVASI versus ZALTRAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MVASI versus ZALTRAP.
MVASI vs ZALTRAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing binding to VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Vascular endothelial growth factor (VEGF) trap; binds to VEGF-A, VEGF-B, and PlGF, inhibiting angiogenesis.
5 mg/kg intravenously every 2 weeks for metastatic colorectal cancer; 15 mg/kg intravenously every 3 weeks for non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer.
4 mg/kg intravenously over 1 hour every 2 weeks
None Documented
None Documented
Approximately 20 days (range 11–50 days); typical dosing interval every 2–3 weeks.
17-18 days (terminal half-life) with clinical context supporting a dosing interval of every 2 weeks; steady-state achieved by approximately 16 weeks.
Primarily metabolized via reticuloendothelial system; no significant renal or biliary excretion of intact drug.
Primarily via the reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Renal elimination accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor